Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019048639) MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/048639 International Application No.: PCT/EP2018/074201
Publication Date: 14.03.2019 International Filing Date: 07.09.2018
IPC:
A61K 38/17 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
VIB VZW [BE/BE]; Rijvisschestraat 120 9052 Gent, BE
UNIVERSITEIT GENT [BE/BE]; Sint-Pietersnieuwstraat 25 9000 Gent, BE
Inventors:
SAELENS, Xavier; BE
VAN HOECKE, Lien; BE
DE KOKER, Stefaan; BE
GROOTEN, Johan; BE
Common
Representative:
VIB VZW; Rijvisschestraat 120 9052 Gent, BE
Priority Data:
17189929.707.09.2017EP
1808377.422.05.2018GB
Title (EN) MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN IN IMMUNOTHERAPEUTIC CANCER CONTROL
(FR) PROTÉINE DE TYPE DOMAINE KINASE À LIGNÉE MIXTE DANS LE TRAITEMENT IMMUNOTHÉRAPEUTIQUE DU CANCER
Abstract:
(EN) The invention relates to the field of immuno-oncology. More in particular, it relates to applying the mixed-lineage kinase domain-like protein (MLKL) or variants thereof in immunotherapeutic treatment of cancer. The MLKL or variant thereof is inducing an adaptive immune response to cancer cells leading to treatment of primary tumors and preventing development of secondary tumor or tumor metastasis.
(FR) L'invention concerne le domaine de l'immuno-oncologie. Plus particulièrement, l'invention concerne l'application de la protéine de type domaine kinase à lignée mixte (MLKL) ou de variants de celle-ci dans le traitement immunothérapeutique du cancer. La MLKL ou son variant induit une réponse immunitaire adaptative aux cellules cancéreuses conduisant au traitement des tumeurs primaires et à la prévention du développement d'une tumeur secondaire ou d'une métastase tumorale.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)